ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

The Pharma Comms Impact Conference - For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day

Unions call on US antitrust regulators to block $63 billion ...

US antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion merger of AbbVie and Allergan, according to a press report.

Rova-T: the story of AbbVie’s multi-billion dollar failure

Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T.

The top pharma companies by revenue 2018

AbbVie axes multi-billion cancer flop Rova-T after another t...

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.